Cancel anytime
Kodiak Sciences Inc (KOD)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/12/2024: KOD (4-star) is a STRONG-BUY. BUY since 43 days. Profits (189.62%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 234.7% | Upturn Advisory Performance 3 | Avg. Invested days: 40 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 12/12/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 234.7% | Avg. Invested days: 40 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 12/12/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 470.46M USD |
Price to earnings Ratio - | 1Y Target Price 6.67 |
Dividends yield (FY) - | Basic EPS (TTM) -3.41 |
Volume (30-day avg) 471838 | Beta 2.25 |
52 Weeks Range 2.19 - 11.60 | Updated Date 12/12/2024 |
Company Size Small-Cap Stock | Market Capitalization 470.46M USD | Price to earnings Ratio - | 1Y Target Price 6.67 |
Dividends yield (FY) - | Basic EPS (TTM) -3.41 | Volume (30-day avg) 471838 | Beta 2.25 |
52 Weeks Range 2.19 - 11.60 | Updated Date 12/12/2024 |
Earnings Date
Report Date 2024-11-12 | When Before Market |
Estimate -0.9 | Actual -0.84 |
Report Date 2024-11-12 | When Before Market | Estimate -0.9 | Actual -0.84 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.72% | Return on Equity (TTM) -71.5% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 346027539 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 |
Shares Outstanding 52623800 | Shares Floating 32200902 |
Percent Insiders 5.66 | Percent Institutions 77.79 |
Trailing PE - | Forward PE - | Enterprise Value 346027539 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52623800 | Shares Floating 32200902 |
Percent Insiders 5.66 | Percent Institutions 77.79 |
Analyst Ratings
Rating 2.88 | Target Price 4 | Buy - |
Strong Buy 1 | Hold 4 | Sell 3 |
Strong Sell - |
Rating 2.88 | Target Price 4 | Buy - | Strong Buy 1 |
Hold 4 | Sell 3 | Strong Sell - |
AI Summarization
Kodiak Sciences Inc. Overview
Company Profile:
History and Background: Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California. They focus on developing novel therapies for ophthalmic diseases.
Core Business Areas: Kodiak focuses on developing antibody-based therapies for the treatment of retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
Leadership Team:
- Vincent J. O’Day, President & CEO
- Lisa A. Diller, Chief Medical Officer
- Michael S. Chang, Chief Financial Officer
- Douglas A. Losordo, PhD, Chief Scientific Officer & Executive Vice President
- John P. Hutchinson, Executive Vice President, Commercial
- Mary E. Hayes, Executive Vice President, General Counsel & Corporate Secretary
Top Products and Market Share:
Top Products:
- KSI-301: Anti-VEGF therapy for the treatment of wet AMD (Phase 3)
- KSI-302: Anti-Tie-2 therapy for the treatment of DR (Phase 1/2)
- KSI-303: Anti-Ang2 therapy for the treatment of DME (Preclinical)
Market Share: Kodiak does not currently have any marketed products. KSI-301, the company's lead product candidate, is in Phase 3 clinical trials for wet AMD, a market estimated at $12 billion.
Product Performance and Market Reception: KSI-301 has demonstrated positive results in clinical trials, showing efficacy and safety comparable to existing anti-VEGF therapies.
Comparison to Competitors: Kodiak's key competitors in the anti-VEGF market include Regeneron Pharmaceuticals (REGN), Roche Holding AG (RHHBY), and Novartis AG (NVS). KSI-301 has the potential to offer advantages in terms of dosing frequency and safety profile compared to existing therapies.
Total Addressable Market:
- Global: The global market for retinal vascular diseases is estimated to be $28 billion.
- US: The US market for retinal vascular diseases is estimated to be $11 billion.
Financial Performance:
Financial Statements: Kodiak is currently in the clinical development stage and has not yet generated any significant revenue. As of June 30, 2023, the company had $302.5 million in cash and equivalents.
Year-Over-Year Performance: Revenue and net income are not applicable at this stage.
Cash Flow and Balance Sheet Health: Kodiak is currently funded through private investment and has a strong cash position.
Dividends and Shareholder Returns:
- Dividends: Kodiak does not currently pay dividends.
- Shareholder Returns: Since its IPO in 2021, Kodiak's stock price has decreased by approximately 50%.
Growth Trajectory:
- Historical Growth: Due to its early stage, the company's historical growth is not relevant.
- Future Growth: The success of KSI-301 and other pipeline candidates will be critical for future growth.
Market Dynamics:
- Trends: The anti-VEGF market is growing due to the increasing prevalence of retinal vascular diseases.
- Demand-Supply: There is a high demand for effective and safe treatments for retinal vascular diseases, and KSI-301 has the potential to meet this need.
- Technological Advancements: Advances in antibody engineering and drug delivery technologies are driving innovation in the field.
Market Position and Adaptability: Kodiak is well-positioned in the growing anti-VEGF market with its differentiated product candidates.
Competitors:
- Regeneron Pharmaceuticals (REGN): Market leader with Eylea, a leading anti-VEGF therapy for wet AMD.
- Roche Holding AG (RHHBY): Offers Lucentis, another major anti-VEGF therapy for wet AMD.
- Novartis AG (NVS): Markets Beovu, a newer anti-VEGF therapy for wet AMD.
- Ocugen, Inc. (OCGN): Developing gene therapy candidates for retinal diseases, including Ocriplasmin for vitreomacular adhesion.
- Apellis Pharmaceuticals, Inc. (APLS): Developing complement-based therapies for retinal diseases, including pegcetacoplan for geographic atrophy.
Competitive Advantages:
- Differentiated product candidates: KSI-301 has the potential to offer a longer duration of action and improved safety profile compared to existing anti-VEGF therapies.
- Experienced leadership team: Kodiak has a strong leadership team with deep experience in ophthalmology and drug development.
- Strong financial position: The company has a significant cash runway to support its clinical development programs.
Competitive Disadvantages:
- Early-stage development: KSI-301 has not yet been approved by the FDA.
- Limited commercial experience: Kodiak has no experience in commercializing drugs.
Potential Challenges and Opportunities:
Key Challenges:
- Competition: Kodiak faces stiff competition from established players in the anti-VEGF market.
- Clinical development: The company needs to successfully navigate the clinical development process for KSI-301 and other pipeline candidates.
- Commercialization: If approved, Kodiak will need to establish a strong commercial infrastructure to compete in the market.
Potential Opportunities:
- Growing market: The market for retinal vascular diseases is expected to continue growing, creating significant opportunity for new therapies.
- Product differentiation: KSI-301 has the potential to offer advantages over existing therapies, which could help capture market share.
- Expansion into new markets and indications: Kodiak could expand into new markets and indications with its product candidates.
Recent Acquisitions (last 3 years): Kodiak has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
- Rating: 7 out of 10
- Rationale: Kodiak has a strong pipeline of differentiated product candidates, an experienced leadership team, and a solid financial position. However, the company faces challenges in the form of competition, clinical development, and commercialization.
Sources and Disclaimers:
- Kodiak Sciences Inc. website: https://www.kodiaksciences.com/
- SEC filings: https://www.sec.gov/cgi-bin/browse-edgar?company=kodiak+sciences+inc&owner=exclude&action=getcompany
- Market research reports from industry sources
Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
This overview aims to provide a comprehensive analysis of Kodiak Sciences Inc. based on publicly available information as of November 2023. The information presented here should be considered in the context of your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange | NASDAQ | Headquaters | Palo Alto, CA, United States |
IPO Launch date | 2018-10-04 | Co-Founder, Chairman, CEO & President | Dr. Victor Perlroth M.D. |
Sector | Healthcare | Website | https://kodiak.com |
Industry | Biotechnology | Full time employees | 111 |
Headquaters | Palo Alto, CA, United States | ||
Co-Founder, Chairman, CEO & President | Dr. Victor Perlroth M.D. | ||
Website | https://kodiak.com | ||
Website | https://kodiak.com | ||
Full time employees | 111 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.